| Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. | |
| | |
MedLine Citation:
|
PMID: 10579118 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Iron is pivotal is producing tissue-damaging reactive oxygen metabolites. Our aim is to determine the antiinflammatory activity of deferiprone, an oral iron chelator, in experimental colitis and gastritis. Colitis was induced by intraceccal administration of 2 ml 5% acetic acid or by intracolonic administration of 0.1 ml 3% iodoacetamide, with or without cotreatment with deferiprone. Gastritis was induced by intragastric administration of ethanol or hydrochloric acid (HCl) and by subcutaneous injection of indomethacin, with and without deferiprone. Rats were killed 24 hours after acetic acid and iodoacetamide, 30 minutes after ethanol, one hour after HCl, and three hours after indomethacin administration. The colon or stomach was isolated, macroscopic damage was measured, and mucosal samples were obtained for determination of eicosanoid generation, myeloperoxidase (MPO), and nitric oxide synthase (NOS) activities. Deferiprone decreased iodoacetamide and acetic acid-induced macroscopic colonic damage by 67% and 69%, respectively, and macroscopic gastric damage by 91%, 68%, and 46% induced by ethanol, HCl, and indomethacin, respectively. The effect of deferiprone was accompanied by significant decrease in colonic and gastric, MPO and NOS activities, and colonic prostaglandin E2 (PGE2) generation, in acetic acid, ethanol, and indomethacin models, whereas in the iodoacetamide and HCl models attenuation of the decrease in PGE2 generation was seen. Deferiprone is protective in experimental colitis and gastritis, probably due to decreased production of iron-dependent oxygen-free radicals. Oral iron chelators may constitute a novel approach to ameliorate gastrointestinal inflammatory disorders. |
| | |
Authors:
|
J Ablin; O Shalev; E Okon; F Karmeli; D Rachmilewitz |
Related Documents
:
|
10832068 - Tetradecylthioacetic acid and tetradecylselenoacetic acid inhibit lipid peroxidation an... 11777398 - Use of iron monocarboxylates in the two-step preparation of poly(ester-urethane)s. 18367828 - Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid level... 20184028 - Lipoxygenase inhibitory activity of 6-pentadecanylsalicylic acid without prooxidant eff... 3770318 - Gastric acid response to pentagastrin and gastrin-releasing peptide in conscious cats. 7460478 - Kinetics of single doses of fenbufen in patients with renal insufficiency. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Inflammatory bowel diseases Volume: 5 ISSN: 1078-0998 ISO Abbreviation: Inflamm. Bowel Dis. Publication Date: 1999 Nov |
Date Detail:
|
Created Date: 1999-12-21 Completed Date: 1999-12-21 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9508162 Medline TA: Inflamm Bowel Dis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 253-61 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Hadassah University Hospital, Mount Scopus, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetic Acids Administration, Oral Animals Colitis / chemically induced, complications* Disease Models, Animal Gastric Mucosa / drug effects, pathology Gastritis / chemically induced, complications* Indomethacin Intestinal Mucosa / drug effects, pathology Iodoacetamide Iron Chelating Agents / administration & dosage* Male Pyridones / administration & dosage* Rats Rats, Sprague-Dawley Statistics, Nonparametric Stomach Ulcer / drug therapy*, etiology, pathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Acetic Acids; 0/Iron Chelating Agents; 0/Pyridones; 144-48-9/Iodoacetamide; 30652-11-0/deferiprone; 53-86-1/Indomethacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificit...
Next Document: Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to e...